Cue Biopharma secures exclusive licence for Phase 2 allergy antibody

8 articles · Updated · MarketWatch · Apr 30

The deal with Ascendant Health Sciences includes a $15 million upfront fee and up to $676.5 million in milestone payments, plus tiered royalties.
The antibody is being tested by Genesis Life Sciences in a Phase 2 chronic spontaneous urticaria trial in China, with results expected in the second half of 2026.
Cue also named former Acelyrin chief Shao-Lee Lin as CEO, replacing interim chief Lucinda Warren, and plans a global Phase 2b food allergy trial after reviewing the China data.

Is Cue Biopharma's $676M bet on a new antibody the future of allergy treatment?

Can a new CEO and a licensed drug rescue a biotech company previously facing financial collapse?